Claims for Patent: 9,790,208

Summary for Patent: 9,790,208

Title:	Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-- yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
Abstract:	The invention relates to a crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-- yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone hydrochloride, processes for the preparation thereof, pharmaceutical compositions containing said crystalline form, and its use as medicament, especially as orexin receptor antagonist.
Inventor(s):	Boss; Christoph (Allschwil, CH), Brotschi; Christine (Allschwil, CH), Gude; Markus (Allschwil, CH), Heidmann; Bibia (Allschwil, CH), Sifferlen; Thierry (Allschwil, CH), Von Raumer; Markus (Allschwil, CH), Williams; Jodi T. (Allschwil, CH)
Assignee:	IDORSIA PHARMACEUTICALS LTD (Allschwil, CH)
Application Number:	15/101,832
Patent Claims:	1. A crystalline form of the compound (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazole-2-yl)-2-methylpyrrolidin-1- -yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone; wherein said compound is present in form of the hydrochloric acid salt; wherein said crystalline salt form comprises peaks in the X-ray powder diffraction diagram at the following angles of refraction 2.theta.: 11.0.degree., 24.1.degree. and 24.5.degree., wherein said X-ray powder diffraction diagram is obtained by using combined Cu K.alpha.1 and K.alpha.2 radiation, without K.alpha.2 stripping; and the accuracy of the 2.theta. values is in the range of 2.theta.+/-0.2.degree.. 2. A crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazole-2-yl)-2-methylpyrrolidin-1- -yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone hydrochloride according to claim 1, comprising peaks in the X-ray powder diffraction diagram at the following angles of refraction 2.theta.: 9.2.degree., 11.0.degree., 13.8.degree., 15.1.degree., 16.3.degree., 16.8.degree., 19.8.degree., 24.1.degree., 24.5.degree., and 27.3.degree., wherein said X-ray powder diffraction diagram is obtained by using combined Cu K.alpha.1 and K.alpha.2 radiation, without K.alpha.2 stripping; and the accuracy of the 2.theta. values is in the range of 2.theta.+/-0.2.degree.. 3. A crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazole-2-yl)-2-methylpyrrolidin-1- -yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone hydrochloride according to claim 1, which essentially shows the X-ray powder diffraction pattern as depicted in FIG. 2. 4. A pharmaceutical composition comprising the crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazole-2-yl)-2-methylpyrrolidin-1- -yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone hydrochloride according to claim 1, and a pharmaceutically acceptable carrier. 5. A pharmaceutical composition comprising the crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazole-2-yl)-2-methylpyrrolidin-1- -yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone hydrochloride according to claim 2, and a pharmaceutically acceptable carrier. 6. A pharmaceutical composition comprising the crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazole-2-yl)-2-methylpyrrolidin-1- -yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone hydrochloride according to claim 3, and a pharmaceutically acceptable carrier.